Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome.docVIP

下载本文档

2
0
约2.76万字
约 6页
2017-05-08 发布于上海
举报
版权申诉

Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome

World Journal of Surgical BioMedCentral Case report Open Access Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome Michael Knauer*1,2, Anton Haid1, Karlheinz Ammann1, Alois Lang3, Felix Offner4, Martina Türtscher4, Peter Cerkl5 and Etienne Wenzl1 Address: 1Department of General and Thoracic Surgery, General Hospital of Feldkirch, Academic Teaching Hospital, Feldkirch, Austria, 2University of Human Sciences, Principality of Liechtenstein, General Hospital of Feldkirch, Academic Teaching Hospital, Feldkirch, Austria, 3Department of Internal Medicine, General Hospital of Feldkirch, Academic Teaching Hospital, Feldkirch, Austria, 4Department of Pathology, General Hospital of Feldkirch, Academic Teaching Hospital, Feldkirch, Austria and 5Department of Pulmonology, General Hospital of Feldkirch, Academic Teaching Hospital, Feldkirch, Austria Email: Michael Knauer* - knaui@gmx.at; Anton Haid - anton.haid@lkhf.at; Karlheinz Ammann - chirurgie1@lkhf.at; Alois Lang - chirurgie1@lkhf.at; Felix Offner - chirurgie1@lkhf.at; Martina Türtscher - chirurgie1@lkhf.at; Peter Cerkl - chirurgie1@lkhf.at; Etienne Wenzl - chirurgie1@lkhf.at * Corresponding author Published: 11 October 2007 Received: 13 March 2007 Accepted: 11 October 2007 World Journal of Surgical Oncology 2007, 5:114 doi:10.1186/1477-7819-5-114 This article is available from: /content/5/1/114 ? 2007 Knauer et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Different molecular therapies like the EGFR-inhibiting antibody cetuximab have come into clinical practice. Cetuximab is EMEA-approved for metastatic colorectal cancer and advanced squamous-cell head and neck